HN2005029978A - Formulaciones - Google Patents

Formulaciones

Info

Publication number
HN2005029978A
HN2005029978A HN2005029978A HN2005029978A HN2005029978A HN 2005029978 A HN2005029978 A HN 2005029978A HN 2005029978 A HN2005029978 A HN 2005029978A HN 2005029978 A HN2005029978 A HN 2005029978A HN 2005029978 A HN2005029978 A HN 2005029978A
Authority
HN
Honduras
Prior art keywords
formulations
methods
ecteinascidine
kits
prepare
Prior art date
Application number
HN2005029978A
Other languages
English (en)
Inventor
Calvo Salve Pilar
Tobio Barreira Maria
Hendrik Beijnen Jacob
Nuijen Bastiaan
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35432682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2005029978(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of HN2005029978A publication Critical patent/HN2005029978A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

SE SUMINISTRAN FORMULACIONES DE ECTEINASCIDINA, METODOS PARA PREPARARLAS, ARTICULOS PARA LA FABRICACION Y KITS CON DICHAS FORMULACIONES, Y METODOS PARA TRATAR ENFERMEDADES PROLIFERATIVAS CON DICHAS FORMULACIONES.
HN2005029978A 2004-10-29 2005-10-27 Formulaciones HN2005029978A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62381304P 2004-10-29 2004-10-29

Publications (1)

Publication Number Publication Date
HN2005029978A true HN2005029978A (es) 2009-10-27

Family

ID=35432682

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2005029978A HN2005029978A (es) 2004-10-29 2005-10-27 Formulaciones

Country Status (37)

Country Link
US (2) US8895557B2 (es)
EP (1) EP1658848B1 (es)
JP (1) JP4268163B2 (es)
KR (1) KR101188691B1 (es)
CN (2) CN1823794A (es)
AR (2) AR051653A1 (es)
AT (1) ATE368461T1 (es)
AU (1) AU2005227421B2 (es)
BR (1) BRPI0517238B1 (es)
CA (1) CA2520979C (es)
CY (1) CY1107773T1 (es)
DE (1) DE602005001833T2 (es)
DK (1) DK1658848T3 (es)
ES (1) ES2290844T3 (es)
GT (1) GT200500314A (es)
HK (1) HK1091724A1 (es)
HN (1) HN2005029978A (es)
HR (1) HRP20070374T3 (es)
IL (1) IL182776A (es)
JO (1) JO2464B1 (es)
MX (1) MXPA05011650A (es)
MY (1) MY139049A (es)
NO (1) NO328035B1 (es)
NZ (1) NZ554761A (es)
PA (1) PA8650801A1 (es)
PE (2) PE20100089A1 (es)
PL (1) PL1658848T3 (es)
PT (1) PT1658848E (es)
RS (1) RS50510B (es)
RU (1) RU2382647C2 (es)
SI (1) SI1658848T1 (es)
SV (1) SV2006002283A (es)
TW (1) TWI296523B (es)
UA (1) UA91032C2 (es)
UY (1) UY29183A1 (es)
WO (1) WO2006046079A1 (es)
ZA (1) ZA200703450B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
WO2002036135A2 (en) * 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
IL161430A0 (en) * 2001-10-19 2004-09-27 Pharma Mar Sa Pharmaceutical compositions containing ecteinascidin 743
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
JP2007511499A (ja) * 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
JP2008505862A (ja) * 2004-07-09 2008-02-28 ファルマ、マール、ソシエダード、アノニマ 予後分子マーカー
US20080242670A2 (en) * 2004-09-29 2008-10-02 Pharma Mar S.A., Sociedad Unipersonal Anti-Inflammatory Agents
CN101119750B (zh) * 2004-10-26 2013-03-06 法马马私人股份有限公司 抗癌治疗
DK1658848T3 (da) 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
AU2008313634A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for ET-743 treatment
US20100196272A1 (en) * 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
ES2569180T3 (es) 2010-11-12 2016-05-09 Pharma Mar S.A. Terapia de combinación con un alcaloide antitumoral
BR112013027584B1 (pt) * 2011-04-28 2020-11-03 Oncopeptides Ab preparação farmacêutica liofilizada de dipeptídeos citotóxicos, método para preparar a mesma e uso de sacarose na dita preparação
CN106853252B (zh) * 2015-12-09 2020-03-13 江苏恒瑞医药股份有限公司 曲贝替定药物组合物及其制备方法
CN106880592B (zh) * 2015-12-15 2021-04-06 江苏恒瑞医药股份有限公司 一种曲贝替定的纳米乳及其制备方法
MX2018009088A (es) * 2016-02-04 2018-09-03 Jiangsu Hengrui Medicine Co Composicion farmaceutica inyectable que incluye trabectedina para uso gastrointestinal externo y metodo para la fabricacion de la misma.
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
US20210169873A1 (en) * 2019-10-21 2021-06-10 RK Pharma Solutions LLC Storage-stable ready-to-use injectable formulations of Trabectedin
PE20221338A1 (es) * 2019-11-21 2022-09-13 Pharma Mar Sa Metodos de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina
BR112022020812A2 (pt) 2020-04-15 2022-11-29 Ever Valinject Gmbh Composição farmacêutica compreendendo trabectedina e um aminoacido, formulação liofilizada e uma solução de injeção intravenosa compreendendo dita composição
US20230226051A1 (en) * 2022-01-20 2023-07-20 Extrovis Ag Trabectedin composition

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3774435D1 (de) * 1986-06-09 1991-12-12 Univ Pennsylvania Ekteinascidine 729, 743, 745, 759a, 759b and 770.
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5336669A (en) * 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
DE4242863A1 (de) 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
GB9401447D0 (en) 1994-01-26 1994-03-23 Ciba Geigy Ag Pharmaceutical compositions
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
WO1998052598A1 (en) 1997-05-21 1998-11-26 Genentech, Inc. Novel administration of thrombopoietin
HUP0104273A3 (en) 1998-04-06 2003-12-29 Univ Illinois Semi-synthetic ecteinascidins and pharmaceutical compositions containing them
SK285069B6 (sk) 1998-05-11 2006-05-04 Pharma Mar, S. A. Zlúčeniny, ktoré sú metabolitmi ekteinascidínu 743, farmaceutické prostriedky s ich obsahom a ich použitie
JP2000081438A (ja) 1998-06-25 2000-03-21 Sekisui Chem Co Ltd 被験者の癌化学療法による免疫機能低下の測定方法
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
GB9918178D0 (en) 2000-05-15 1999-10-06 Pharma Mar Sa Synthetic methods
CA2406080C (en) 2000-04-12 2011-11-29 Pharma Mar, S.A. Antitumoral ecteinascidin derivatives
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
US20020137663A1 (en) * 2000-08-11 2002-09-26 Forman Barry M. The anti-neoplastic agent ET-743 inhibits trans activation by SXR
DK1330258T3 (da) * 2000-10-31 2006-05-22 Pharma Mar Sa Kahalalid F-formulering
CA2447553A1 (en) 2000-11-03 2002-05-23 President And Fellows Of Harvard College Saframycins, analogues and uses thereof
WO2002036135A2 (en) * 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
BR0206511A (pt) * 2001-01-25 2003-10-21 Bristol Myeres Squibb Company Formulação parenteral para análogos de epotilona
EP1360337A1 (en) * 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
KR20030081496A (ko) 2001-03-06 2003-10-17 브리스톨-마이어스 스큅 컴퍼니 테가푸르, 우라실, 폴린산, 파클리탁셀 및 카르보플라틴투여를 통한 종양 치료 방법 및 이들의 투여 형태
AU2002242561A1 (en) 2001-03-30 2002-10-15 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
IL161430A0 (en) * 2001-10-19 2004-09-27 Pharma Mar Sa Pharmaceutical compositions containing ecteinascidin 743
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
JP2007511499A (ja) 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
EP1691809A1 (en) 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
WO2005118584A2 (en) 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Saframycin analogs as therapeutic agents in the treatment of cancer
JP2008505862A (ja) * 2004-07-09 2008-02-28 ファルマ、マール、ソシエダード、アノニマ 予後分子マーカー
US20080242670A2 (en) * 2004-09-29 2008-10-02 Pharma Mar S.A., Sociedad Unipersonal Anti-Inflammatory Agents
CN101119750B (zh) 2004-10-26 2013-03-06 法马马私人股份有限公司 抗癌治疗
DK1658848T3 (da) 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
WO2006066183A2 (en) 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Novel saframycin analogs as therapeutic agents
ATE499098T1 (de) * 2005-11-25 2011-03-15 Pharma Mar Sa Verwendung von parp-1-hemmern
AU2007249281A1 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin

Also Published As

Publication number Publication date
DE602005001833D1 (de) 2007-09-13
US20150094313A1 (en) 2015-04-02
JP2006124393A (ja) 2006-05-18
CY1107773T1 (el) 2013-06-19
JO2464B1 (en) 2009-01-20
UY29183A1 (es) 2006-05-31
DE602005001833T2 (de) 2008-04-17
IL182776A0 (en) 2007-08-19
NO20072713L (no) 2007-07-19
HRP20070374T3 (en) 2007-10-31
MXPA05011650A (es) 2006-05-17
RU2382647C2 (ru) 2010-02-27
WO2006046079A1 (en) 2006-05-04
SV2006002283A (es) 2006-07-20
RS50510B (sr) 2010-03-02
TW200621256A (en) 2006-07-01
US20060094687A1 (en) 2006-05-04
ATE368461T1 (de) 2007-08-15
GT200500314A (es) 2007-03-22
PT1658848E (pt) 2007-11-05
DK1658848T3 (da) 2007-11-26
US10322183B2 (en) 2019-06-18
KR101188691B1 (ko) 2012-10-09
TWI296523B (en) 2008-05-11
UA91032C2 (en) 2010-06-25
CN1823794A (zh) 2006-08-30
PL1658848T3 (pl) 2007-12-31
KR20070091121A (ko) 2007-09-07
NO328035B1 (no) 2009-11-10
CN102018714B (zh) 2014-01-08
BRPI0517238B1 (pt) 2021-11-09
US8895557B2 (en) 2014-11-25
CN102018714A (zh) 2011-04-20
ZA200703450B (en) 2008-09-25
AU2005227421A1 (en) 2006-05-18
ES2290844T3 (es) 2008-02-16
CA2520979A1 (en) 2006-02-15
SI1658848T1 (sl) 2007-12-31
HK1091724A1 (en) 2007-01-26
JP4268163B2 (ja) 2009-05-27
AR051653A1 (es) 2007-01-31
CA2520979C (en) 2009-03-24
EP1658848A1 (en) 2006-05-24
PA8650801A1 (es) 2006-09-22
BRPI0517238A (pt) 2008-10-07
AU2005227421B2 (en) 2007-06-28
PE20100089A1 (es) 2010-03-01
MY139049A (en) 2009-08-28
RU2007119724A (ru) 2008-12-10
IL182776A (en) 2010-06-30
EP1658848B1 (en) 2007-08-01
PE20060925A1 (es) 2006-10-23
AR110986A2 (es) 2019-05-22
NZ554761A (en) 2010-01-29

Similar Documents

Publication Publication Date Title
HN2005029978A (es) Formulaciones
NL301145I2 (nl) Tirbanibulin
CY1118760T1 (el) Τροποποιημενα αντισωματα εναντι il-23
CR20110477A (es) Inhibidores de enzimas de proteina cinasa activadas por mitogeno p38
TR201821029T4 (tr) Geliştirilmiş antı-IL-23p19 antikorları.
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
WO2007061874A3 (en) Methods and compositions for use in treating cancer
EA200701918A1 (ru) Белок липокалин
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
CL2009001476A1 (es) Compuestos derivados de 2,4-diamin-n2-fenil pirimidina sustituidos, mediadores de la inhibicion de igf-1r; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades autoinmune, por trasplante, infecciosas o un trastorno proliferativo celular.
GT200600227A (es) Formas solidas cristalinas de tigeciclina y metodos para preparar las mismas
UY31484A1 (es) Piperidinas heteroaril-sustituidas
UY29439A1 (es) Nuevos compuestos
EA200701592A1 (ru) Композиты и способы их получения и использования
GT200500385A (es) Aminoalcoholes triciclicos, procedimientos para su preparacion y su uso como inhibidores de inflamacion
CR9750A (es) Dispersiones solidas amorfas de 7-cloro-n,n,5-trimetil-4-oxo-3-fenil-3,5-dihidro-4h-prirdazino[4,5-b]indol-1-acetamida
ZA200803420B (en) Formulations comprising jorumycin-, reni eramycin-, safracin-related or saframycin-related compounds for treating proliferative diseases
UY29189A1 (es) Nonadepsipeptidos acilados ii
PA8624401A1 (es) Procesos para la preparacion de haluros de aril- y heteroaril-alquilsulfonilo
ATE433459T1 (de) Desoxo-nonadepsipeptide
EA201000864A1 (ru) Фенилоксетанильные производные
DOP2005000223A (es) Nonadepsipeptidos acilados ii
DOP2004000891A (es) Nonadepsipeptidos acilados
CA114273S (en) Haircurler
DE602005015083D1 (de) Amorphes tamsulosin-hydrochlorid